Parkinson Disease Psychosis Clinical Trial
Official title:
Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05824728 -
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
|
Phase 2 | |
| Withdrawn |
NCT05344365 -
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
|
Phase 2 | |
| Recruiting |
NCT05357612 -
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
|
Phase 4 | |
| Completed |
NCT04292223 -
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
|
Phase 4 | |
| Completed |
NCT02969369 -
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
|
Phase 2 | |
| Not yet recruiting |
NCT05995782 -
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
|
Phase 1 | |
| Recruiting |
NCT04579887 -
Presence Hallucination in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT04592965 -
Hallucinations in Parkinson's Disease
|
N/A | |
| Completed |
NCT05240339 -
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
|
||
| Recruiting |
NCT03661125 -
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
|
Early Phase 1 |